Morshuis, M. et al. European experience of DuraHeart magnetically levitated centrifugal left ventricular assist system. Eur. J. Cardiothorac. Surg. 35, 1020-1027

Heart & Diabetes Center, North Rhine-Westphalia, Bad Oeynhausen, Germany.
European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery (Impact Factor: 3.3). 03/2009; 35(6):1020-7; discussion 1027-8. DOI: 10.1016/j.ejcts.2008.12.033
Source: PubMed


The DuraHeart (Terumo Heart, Inc., Ann Arbor, Michigan, USA) is the world's first approved magnetically levitated centrifugal left ventricular assist system designed for long-term circulatory support. We report the clinical outcomes of 68 patients implanted with the DuraHeart as a bridge to cardiac transplantation in Europe.
Sixty-eight patients with advanced heart failure (six females), who were eligible for cardiac transplantation were implanted with the DuraHeart between January 2004 and July 2008. Median age was 58 (range: 29-74) years with 31% over 65 years. Thirty-three of these patients received the device as a part of the European multi-center clinical trial. Survival analyses were conducted for 68 patients and other safety and performance data were analyzed based on 33 trial patients.
Mean support duration was 242+/-243 days (range: 19-1148, median: 161) with a cumulative duration of 45 years. Thirty-five patients (51%) remain ongoing, 18 transplanted, 1 explanted, and 14 died during support with a median time to death of 62 days. The Kaplan-Meier survival rate during support was 81% at 6 months and 77% at 1 year. Of the 13 patients (21%) supported for >1 year, 4 supported for >2 years, 1 supported >3 years, 2 transplanted, 2 died, and 9 ongoing with a mean duration of 744+/-216 days (range: 537-1148, median: 651). Major adverse events included driveline/pocket infection, stroke, bleeding, and right heart failure. There was no incidence of pump mechanical failure, pump thrombosis, or hemolysis.
The DuraHeart was able to provide safe and reliable long-term circulatory support with an improved survival and an acceptable adverse event rate in advanced heart failure patients who were eligible for transplantation.

Download full-text


Available from: Georg Wieselthaler,
  • Source
    • "Third generation devices utilizing magnetic and/or hydrodynamic levitation of the impeller without any contact bearings with the pump include the extra-corporeal systems such as Levitronix CentriMag maglev pump,[40] the magnetically suspended axial flow INCOR (Berlin Heart AG, Berlin, Germany) LVAD,[41] the HeartWare which uses hydrodynamic and magnetic levitation for suspension,[42] the HeartMate III which uses full magnetic suspension[43] and the DuraHeart (Terumo Somerset, USA).[44] "
    [Show abstract] [Hide abstract]
    ABSTRACT: During the last 20 years, the management of heart failure has significantly improved by means of new pharmacotherapies, more timely invasive treatments and device assisted therapies. Indeed, advances in mechanical support, namely with the development of more efficient left ventricular assist devices (LVADs), and the total artificial heart have reduced mortality and morbidity in patients awaiting transplantation, so much so, that LVADs are now approved of as a strategy for destination therapy. In this review, the authors describe in detail the current basic indications, functioning modalities, main limitations of surgical LAVDs, total artificial heart development, and percutaneous assist devices, trying to clarify this complex, but fascinating topic.
    Journal of Geriatric Cardiology 12/2012; 9(4):389-400. DOI:10.3724/SP.J.1263.2012.05281 · 1.40 Impact Factor
  • Source
    • "During a mean support duration of 8 months, there was no incidence of pump mechanical failure, pump thrombosis, or hemolysis. Regarding the device related adverse events the most frequent were neurological complications (27%), right heart failure (27%) and infection, (18%) [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure is a major public health problem and its management requires a significant amount of health care resources. Even with administration of the best available medical treatment, the mortality associated with the disease remains high. As therapeutical strategies for heart failure have been refined, the number of patients suffering from the disease has expanded dramatically. Although heart transplantation still represents the gold standard therapeutical approach, the implantation of mechanical circulatory support devices (MCSDs) evolved to a well-established management for this disease. The limited applicability of heart transplantation caused by a shortage of donor organs and the concurrent expand of the patient population with end-stage heart failure led to a considerable utilization of MCSDs. This paper outlines the current status of mechanical circulatory support.
    Cardiology Research and Practice 08/2012; 2012(1):574198. DOI:10.1155/2012/574198
  • Source
    • "Other complications are bleeding, infections and thromboembolic events. During the succeeding decade, vast improvements in pump design resulted in a new crop of LVADs, whose attributes are transforming LVAD therapy into a kind of standard of care for end-stage heart failure [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]. LVAD therapy has now evolved into a solution which is strikingly superior to optimal medical therapy [4–6, 11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The shortage of appropriate donor organs and the expanding pool of patients waiting for heart transplantation have led to growing interest in alternative strategies, particularly in mechanical circulatory support. Improved results and the increased applicability and durability with left ventricular assist devices (LVADs) have enhanced this treatment option available for end-stage heart failure patients. Moreover, outcome with newer pumps have evolved to destination therapy for such patients. Currently, results using nonpulsatile continuous flow pumps document the evolution in outcomes following destination therapy achieved subsequent to the landmark Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial (REMATCH), as well as the outcome of pulsatile designed second-generation LVADs. This review describes the currently available types of LVADs, their clinical use and outcomes, and focuses on the patient selection process.
    Cardiology Research and Practice 05/2011; 2011(17):290561. DOI:10.4061/2011/290561
Show more